Supplementary Figure 3: Validation of RRAS performance in independent cohort. *In 81 explants that were not used to establish the scoring criteria, ROC curve analysis was used to validate the diagnostic performance of the RRAS in predicting post-transplant HCC recurrence when compared to WHO tumor grade (WHO criteria (dashed line, AUC=0.554), RRAS criteria (solid line, AUC=0.887), n=81). In this independent cohort, RRAS allowed for a more accurate prediction of tumor recurrence following transplantation (p=0.020).*